IASLC 2022 World Conference on Lung Cancer, Vienna, Austria

Expanding horizons in metastatic NSCLC: unmet need and future directions

Please join us for the AstraZeneca sponsored symposium Sunday 7th August, 2022 | 13:15–14:15 CET | Hall C7

Time	Topic	Speaker
13:15–13:20	Welcome and introduction	Chair: John Heymach
13:20–13:35	Biomarker identification of hard-to-treat patients: shining a spotlight on unmet need	Niels Reinmuth
13:35–13:50	Seeing the unseen: techniques and practical strategies for broad molecular profiling	Elena Guerini-Rocco
13:50–14:15	Panel discussion and Q&A	All



Dr John HeymachMD Anderson Cancer Center
Houston, Texas, USA



Prof Niels Reinmuth
Asklepios Lung Clinic
Munich-Gauting, Germany



Dr Elena Guerini-Rocco University of Milan Milan, Italy

AstraZeneca's Commitment to Sustainability



\$19 million invested in environmental efficiency projects in 2020 (NRRGG fund)



CPD A Lists
One of three
companies
worldwide to
achieve double A
listing for Climate
Change and
Water Security
for five
consecutive years



89% of our power is sourced or generated from renewable sources



100% of API (Active Pharmaceutical Ingredient) discharges from AstraZeneca sites were assessed as safe



20% reduction in our water use since 2015



100% of our vehicles will be electric by 2025 This program was approved by the IASLC 2022 World Conference or Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program

This is a non promotional industry symposium organised and sponsored by AstraZenec





AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website